Immunovaccine (TSX-V: IMV) is a clinical stage biotechnology company dedicated to the development of premium vaccines for therapeutic cancer and infectious diseases. The Company has a patented vaccine delivery platform named DepoVax™ which boasts benefits such as enhanced efficacy with fewer doses. The company strengthens its vaccine pipeline through licensing and strategic partnering to help them develop human and animal vaccine products. With positive pre-clinical safety data and partnerships including Pfizer Animal Health, National Cancer Institute, and the National Research Council, the value of our Depovax™ vaccine delivery system has been significantly enhanced.
The DepoVax® platform is a lipid depot-based vaccine enhancement and delivery technology that is able to improve a vaccine performance. Partnership, collaboration and licensing opportunities are available through our DepoVax Challenge and the platform boasts such benefits as enhanced efficacy with fewer doses.
.
Through its own biotech research and collaborations with partners, Immunovaccine has been honoured as one of Canada’s Top 10 Life Sciences Companies. Today, the company is advancing DepoVax-based vaccines in a variety of indications that range from cancer to autoimmune disease through its own pipeline and a number of strategic collaborations and alliances around the world
For more information, please visit
http://www.imvaccine.com/
Specialties
Cancer Vaccines, Vaccine Delivery Platform-DepoVax™, Animal Health
